R&D

P2 FSMP ARDS – perioperative prehabilitation targeting pulmonary complications

P2 FSMP ARDS – perioperative prehabilitation targeting pulmonary complications

Ongoing. FENG, SMART Path 1.1. Consortium with IMDiK PAN. Project value PLN 3,876,072.01, European Funds contribution PLN 3,070,591.86.

The project is co-financed by the European Funds under the European Funds for a Modern Economy 2021-2027 programme, SMART Path (Measure 1.1).

Project title: P2 FSMP ARDS – perioperative prehabilitation targeting pulmonary complications
Beneficiary: Pellicarnos S.A., in a consortium with the Mossakowski Medical Research Institute of the Polish Academy of Sciences
Project value: PLN 3,876,072.01
European Funds contribution: PLN 3,070,591.86

Pellicarnos

Project objective: to develop and clinically validate a food for special medical purposes, taken in the perioperative period as part of prehabilitation, to reduce the risk of postoperative pulmonary complications.

Target group: adult patients undergoing elective surgery with an increased risk of respiratory complications, and surgical and anaesthesiology centres.

Clinical relevance

The subject of the R&D work is the development and clinical validation of a product innovation in the category of foods for special medical purposes (FSMP), to be taken in the perioperative period with the aim of preventing postoperative pulmonary complications (PPC) and reducing the risk of acute respiratory distress syndrome (ARDS).

The need for the product stems from the scale of PPC, including ARDS, which has a mortality rate of up to 40%, particularly among older patients. According to the Berlin Definition adopted by the European Society of Intensive Care Medicine, ARDS is an acute condition (developing within one week), the radiological lung changes are bilateral, and its characteristic feature is hypoxaemia caused by impaired pulmonary gas exchange. The cause may be a pulmonary (as in PPC) or extrapulmonary disease process. The initiating event is most often damage to alveolar epithelial cells, followed by pulmonary oedema, activation of inflammation and oxidative stress.

Clinical studies have shown that pharmacological interventions at the stage of established ARDS in adult patients are not effective, even when they are effective in animal models. This applies, for example, to intratracheal administration of pulmonary surfactant. In ARDS models induced by intratracheal LPS, therapeutic agents were almost always given immediately before the toxin or later. In adult patients, the disease process in the lungs begins several days earlier and is visible in changes in biological markers. It is therefore reasonable to look for ways of counteracting ARDS that stop or limit its development at an early stage, when it can still be diagnosed.

The Pellicarnos project addresses this gap: we are investigating whether a composition taken before surgery affects surfactant production, oxidative stress and inflammation, and thereby helps preserve lung function.

Scope of R&D work

  • Preclinical phase: assessment of the product in an LPS-induced ARDS model, analysing its effect on inflammation, oxidative stress and lung integrity.
  • ODT formulation (orally disintegrating tablets): development of a convenient oral form with high bioavailability, adapted to the needs of patients before surgery.
  • Clinical phase: a study in patients undergoing elective surgery with a high risk of respiratory complications, assessing the product’s effectiveness as part of prehabilitation.
  • Scale-up: transfer of the technology from laboratory to semi-industrial scale.

Innovation

The project’s outcome stands out for:

  • a non-obvious composition, filed with the Polish Patent Office,
  • an ODT formulation that can be used by patients who have difficulty taking standard oral forms,
  • early intervention, before full-blown ARDS develops,
  • the use of molecular markers to assess the effectiveness of the intervention.

#EUFunds

European Funds for a Modern Economy, Republic of Poland, Co-funded by the European Union, National Centre for Research and Development

Pellicarnos
Privacy Overview

This website uses cookies to provide you with the best possible experience. Information about cookies is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team understand which sections of the site are most interesting and useful to you.